# US 2025/0082708 A1 · Herbal composition for use in the treatment or prevention of postpartum depression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082708 A1
- Document ID: US20250082708A1
- Status: Published application
- Kind: A1
- Application number: 18/868,078
- Filed: 2023-05-24
- Published: 2025-03-13
- Earliest claimed: 2022-05-25
- Assignees: Cristalfarma S.R.L.
- Applicants: Cristalfarma S.R.L.
- Inventors: Maria Cristina Del Bono; Francesco Bonomo
- Web page: https://patentgrep.com/patent/US20250082708A1

## CPC

- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns a composition comprising, as active ingredients: —dry extract of Withania somnifera, —dry extract of Melissa officinalis, —microencapsulated essential oil of Lavandula angustifolia, and —optionally, Vitamin D3 for use in the prevention and/or in the treatment of postpartum depression (PPD).

## Claims

### Claim 1

A method for the prevention and/or the treatment of postpartum depression (PPD) said method comprising
administering a composition comprising, as active ingredients:
dry extract of Withania somnifera (L.),
dry extract of Melissa officinalis (L.), and
microencapsulated essential oil of Lavandula angustifolia.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the composition is an adjuvant of pharmacological therapies.

### Claim 3 (depends on 1)

The method according to claim 1, for in the prevention of PPD in
pregnant women, or
puerperal women in the neonatal period comprised between 0 and 6 weeks after delivery.

### Claim 4 (depends on 1)

The method according to claim 1, for the treatment of PPD of puerperal women.

### Claim 5 (depends on 4)

The method according to claim 4, for the treatment of PPD of puerperal women in the neonatal period comprised between 0 weeks and 24 months.

### Claim 6 (depends on 1)

The method according to claim 1, wherein PPD is characterized by a symptomatology selected from the group consisting of: rapid mood swings, irritability, anxiety or panic attacks, decrease of concentration, crying crisis; appetite disorders; sleep disorders or insomnia even when the child sleeps; psychomotor agitation or slowdown; fatigue/tiredness; suicidal thoughts; depressed mood; loss of libido; headaches and myalgias; excessive concerns or disinterest in the baby; feeling of uselessness or inadequacy as a mother; sense of guilt; fear of harming the baby and combinations thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition comprises
dry extract of Withania somnifera in a concentration comprised between 30% and 40% (w/w),
dry extract of Melissa officinalis, in a concentration comprised between 20% and 30% (w/w),
microencapsulated essential oil of Lavandula angustifolia, in concentration comprised between 20% and 30% (w/w),
per administration unit.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the composition comprises, as a further active ingredient vitamin D3.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition is administered daily by a dosage of 1 or 2 administration units.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the composition is in solid form.

### Claim 11 (depends on 3)

The method according to claim 3, wherein said pregnant women are between the 35th and 40th week of pregnancy.

### Claim 12 (depends on 8)

The method according to claim 8, wherein said vitamin D3 is in concentration comprised between 3% and 8% (w/w) per administration unit.

### Claim 13 (depends on 10)

The method according to claim 10, wherein said solid form is the form of tablet, capsule or powder.
